Search results
Search for "RNAi" in Full Text gives 7 result(s) in Beilstein Journal of Organic Chemistry.
The role of chemistry in the success of oligonucleotides as therapeutics
Beilstein J. Org. Chem. 2022, 18, 197–199, doi:10.3762/bjoc.18.22
- messenger (mRNA) to stop the synthesis of proteins using short strands of DNA, now known as antisense oligonucleotides, was first coined about 40 years ago [1]. Almost 20 years later, another endogenous mechanism, known as RNA interference (RNAi) was discovered when it was shown that short stretches of
- effective in patisiran, the first RNAi drug to reach patients. Lipid nanoparticles are also being used in the new generation of RNA vaccines for tackling the COVID pandemic. Another noteworthy advancement is the ease and scale with which oligonucleotides are being produced today. Without access to larger
Antiviral therapy in shrimp through plant virus VLP containing VP28 dsRNA against WSSV
Beilstein J. Org. Chem. 2021, 17, 1360–1373, doi:10.3762/bjoc.17.95
- applied to pathogen control in shrimp and also other organisms, widening the application window in nanomedicine. Keywords: antiviral therapy; CCMV; oral administration; P. vannamei; plant VLPs; RNAi; VP28; white spot syndrome virus; Introduction The white spot syndrome virus (WSSV) is recognized as one
- control [7]. So far several strategies have been reported to control the WSSV, including activation of the immune system, DNA vaccines, herbal extracts, and RNA interference (RNAi) [8][9]. Among them, the RNAi technology has shown great potential to protect shrimp against the WSSV in some lab-scale
- experiments [10][11]. The RNAi mechanism comprises a set of cellular processes of posttranscriptional gene silencing that begins with administering the double-stranded RNA (dsRNA). It concludes with a specific gene silencing based on sequence homology between the digested fragments of the dsRNA and the gene
Beyond ribose and phosphate: Selected nucleic acid modifications for structure–function investigations and therapeutic applications
Beilstein J. Org. Chem. 2021, 17, 908–931, doi:10.3762/bjoc.17.76
- DNA G:C > A:T whereas in homo-DNA (2',3'-β-ᴅ-dideoxyglucopyranose nucleic acid) G:C > A:A ≈ G:G > A:T (reverse Hoogsteen A:A and G:G pairs) ([40] and cited references). Messenger RNA is the target of both the antisense and RNAi strategies to interfere with biological information transfer prior to
- revealed that thermal stabilization may be attributed to nonconventional hydrogen bonds in the backbone [195][196][197]. Gene silencing by RNAi has also been explored with siRNA containing FANA residues [198]. These studies have shown that FANA is accommodated in the sense strand and 5'-end and 3'-termini
- structural distortions caused by A/B junctions within the helical structures [207]. 2',4'-diF-modified siRNA sequences were capable of triggering RNAi with high efficiency, and the incorporation of multiple residues in the guide (antisense) strand yielded more potent siRNAs than those containing LNA or FANA
Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides
Beilstein J. Org. Chem. 2021, 17, 891–907, doi:10.3762/bjoc.17.75
- the usefulness of aptamer-loaded LNPs to increase target cell specificity and potentially deliverability of central-nervous-system-active RNAi therapeutics across the BBB. Keywords: aptamer; blood–brain barrier; gene therapy; HIV-1; lipid nanoparticle; Introduction Lipid nanoparticles (LNPs
Anthelmintic drug discovery: target identification, screening methods and the role of open science
Beilstein J. Org. Chem. 2020, 16, 1203–1224, doi:10.3762/bjoc.16.105
- anthelmintic drug targets from a parasitic worm [95][96]. These approaches are still in their infancy, but such genetic modifications can give rise to scorable phenotypes reflecting the properties of the parasite drug target which may in future lend themselves to high-throughput chemical and genetic (RNAi
Stimuli-responsive oligonucleotides in prodrug-based approaches for gene silencing
Beilstein J. Org. Chem. 2018, 14, 436–469, doi:10.3762/bjoc.14.32
- , more potent than AONs or ribozymes for gene knockdown, is centered on the RNA interference (RNAi) mechanism, which uses two natural pathways for gene silencing. One is guided by double-stranded siRNAs of 19–23 nucleotides in length that are fully complementary to the mRNA targets, and the other is
- noncytotoxic fashion. Next, the authors prepared conjugates of the siRNNs via one A-SATE phosphotriester with a hepatocyte-specific tris-N-acetylgalactosamine targeting domain and demonstrated a stronger RNAi response in mouse liver (following subcutaneous or intravenous administration) than the same
- conjugates with non-enzymolabile phosphotriesters as reference compounds. In conclusion, from this relevant study, it is noteworthy that for the first time, siRNA prodrugs have been synthesized by a versatile method and are intracellularly converted into natural phosphodiester siRNAs that induce robust RNAi
Multivalent dendritic polyglycerolamine with arginine and histidine end groups for efficient siRNA transfection
Beilstein J. Org. Chem. 2015, 11, 763–772, doi:10.3762/bjoc.11.86
- ; Introduction Since the discovery of RNA interference (RNAi) and awareness of its role in posttranscriptional gene silencing, tremendous efforts and capital have been devoted to the development of therapeutics based on this pathway [1]. So far, there are at least 22 RNAi-based drugs in clinical trials and many
Other Beilstein-Institut Open Science Activities
